Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDImmuneering Corp Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 3 | -$0.26 | -$0.24 | -$0.25 |
| Q2 2026 | 3 | -$0.28 | -$0.28 | -$0.28 |
| Q3 2026 | 1 | -$0.33 | -$0.33 | -$0.33 |
| Q4 2026 | 1 | -$0.37 | -$0.37 | -$0.37 |
| Q1 2027 | 1 | -$0.36 | -$0.36 | -$0.36 |
| Q2 2027 | 1 | -$0.41 | -$0.41 | -$0.41 |
| Q3 2027 | 1 | -$0.43 | -$0.43 | -$0.43 |
| Q4 2027 | 1 | -$0.45 | -$0.45 | -$0.45 |
Immuneering Corp Earnings Date And Information
Immuneering Corp last posted its earnings results on Friday, March 6th, 2026. The company reported $-0.18 earnings per share for the quarter, topping analysts' consensus estimates of $-0.31 by $0.13. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Immuneering Corp has generated $-1 earnings per share over the last year ($-1.27 diluted earnings per share) and currently has a price-to-earnings ratio of -4.23. Immuneering Corp has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Immuneering Corp Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/06/2026 | Q4 2025 | -$0.31 | -$0.18 | 0.13 | $0 | $0 |
| 11/12/2025 | Q3 2025 | -$0.37 | -$0.38 | -0.01 | $0 | $0 |
| 08/13/2025 | Q2 2025 | -$0.40 | -$0.40 | 0 | N/A | $0 |
| 05/05/2025 | Q1 2025 | -$0.41 | -$0.42 | -0.01 | N/A | $0 |
| 03/20/2025 | Q4 2024 | -$0.42 | -$0.58 | -0.16 | N/A | $0 |
| 11/13/2024 | Q3 2024 | -$0.54 | -$0.49 | 0.05 | N/A | $0 |
| 08/06/2024 | Q2 2024 | -$0.51 | -$0.47 | 0.04 | N/A | $0 |
| 05/07/2024 | Q1 2024 | -$0.45 | -$0.49 | -0.04 | N/A | $0 |
| 03/01/2024 | Q4 2023 | -$0.48 | -$0.52 | -0.04 | N/A | $0 |
| 11/09/2023 | Q3 2023 | -$0.51 | -$0.43 | 0.08 | N/A | $0 |
| 08/03/2023 | Q2 2023 | -$0.54 | -$0.43 | 0.11 | N/A | $0 |
| 05/04/2023 | Q1 2023 | -$0.54 | $40.16 | 40.7 | N/A | $0 |
| 03/06/2023 | Q4 2022 | -$0.58 | -$0.47 | 0.11 | N/A | $455 |
| 11/10/2022 | Q3 2022 | -$0.48 | -$0.47 | 0.01 | N/A | $38.38 K |
| 08/10/2022 | Q2 2022 | -$0.52 | -$0.44 | 0.08 | N/A | $94.42 K |
| 05/10/2022 | Q1 2022 | -$0.44 | -$0.49 | -0.05 | N/A | $183.70 K |
| 03/10/2022 | Q4 2021 | -$0.39 | -$0.42 | -0.03 | N/A | $189.59 K |
| 11/09/2021 | Q3 2021 | -$0.61 | -$0.47 | 0.14 | N/A | $482.13 K |
| 09/09/2021 | Q2 2021 | -$1.44 | -$0.33 | 1.11 | N/A | $660.04 K |
| 03/30/2021 | Q1 2021 | N/A | -$0.46 | N/A | N/A | $748.20 K |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Immuneering Corp Earnings: FAQ's
In the previous quarter, Immuneering Corp (:IMRX) reported $-0.18 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.31 by $0.13.
The conference call for Immuneering Corp's latest earnings report can be listened to online.
The conference call transcript for Immuneering Corp's latest earnings report can be read online.
Immuneering Corp (:IMRX) has a recorded net income of $-56,024,898.Immuneering Corp has generated $-1.27 earnings per share over the last four quarters.
Immuneering Corp (:IMRX) has a price-to-earnings ratio of -4.23 and price/earnings-to-growth ratio is -0.11.